Universal CAR T-Cells aim to tame autoimmune attacks in early trial
NCT ID NCT06941129
First seen Oct 01, 2025 · Last updated May 13, 2026 · Updated 31 times
Summary
This study tests a new treatment using specially engineered immune cells (CAR T-cells) that target two proteins, CD19 and BCMA, found on faulty immune cells. The goal is to see if it is safe and can help control severe autoimmune diseases like lupus and scleroderma that have not responded to other treatments. The trial involves 12 adults and focuses on monitoring side effects and any improvement in disease activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, China
Conditions
Explore the condition pages connected to this study.